Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original paper

VARS2 V552V variant as prognostic marker in patients with early breast cancer

Authors: Yee Soo Chae, Soo Jung Lee, Joon Ho Moon, Byung Woog Kang, Jong Gwang Kim, Sang Kyun Sohn, Jin Hyang Jung, Ho Yong Park, Ji Young Park, Hye Jung Kim, Sang-Woo Lee

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

The present study analyzed the polymorphisms of DNA repair genes and their impact on the survival of 240 patients with early breast cancer. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen polymorphisms in 12 DNA repair genes were determined using the Sequenom Mass array system. Among the target polymorphisms, VARS2 rs2074511 and POLE rs5744857 were found to correlate with survival after curative surgery in a log-rank test. No difference was found in the clinical and tumor characteristics according to the genotypes of these two coding variants, except for a higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (P = 0.025). Meanwhile, a multivariate analysis showed that the GG genotype of VARS2 V552 V (rs2301717) was significantly associated with disease-free survival (DFS; HR = 0.298; P = 0.044) and marginally with distant DFS (DDFS; HR = 0.266; P = 0.077). In particular, the VARS2 rs2074511 polymorphism was only associated with survival in patients with triple negative (TN)-type breast cancer (P = 0.018 for DFS and 0.042 for DDFS, respectively). In conclusion, VARS2 V552V may be considered as a prognostic factor for survival in patients with early breast cancer.
Literature
1.
go back to reference Trojan J, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. 2002;122(1):211–9.PubMedCrossRef Trojan J, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. 2002;122(1):211–9.PubMedCrossRef
2.
go back to reference Hutter P, Couturier A, Rey-Berthod C. Two common forms of the human MLH1 gene may be associated with functional differences. J Med Genet. 2000;37(10):776–81.PubMedCrossRef Hutter P, Couturier A, Rey-Berthod C. Two common forms of the human MLH1 gene may be associated with functional differences. J Med Genet. 2000;37(10):776–81.PubMedCrossRef
3.
go back to reference Shin A, et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev. 2008;9(3):501–5.PubMed Shin A, et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev. 2008;9(3):501–5.PubMed
4.
go back to reference Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513–30.PubMed Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513–30.PubMed
5.
go back to reference Li J, et al. Genetic polymorphisms in the DNA repair enzyme ERCC2 and breast tumour risk in a Chinese population. J Int Med Res. 2008;36(3):479–88.PubMed Li J, et al. Genetic polymorphisms in the DNA repair enzyme ERCC2 and breast tumour risk in a Chinese population. J Int Med Res. 2008;36(3):479–88.PubMed
6.
go back to reference Pooley KA, et al. Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3482–9.PubMedCrossRef Pooley KA, et al. Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3482–9.PubMedCrossRef
7.
go back to reference Poplawski T, et al. Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression. Breast Cancer Res Treat. 2005;94(3):199–204.PubMedCrossRef Poplawski T, et al. Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression. Breast Cancer Res Treat. 2005;94(3):199–204.PubMedCrossRef
8.
go back to reference Shu XO, et al. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1462–7.PubMed Shu XO, et al. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1462–7.PubMed
9.
go back to reference Yuan HY, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34(Web Server issue):W635–41.PubMedCrossRef Yuan HY, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34(Web Server issue):W635–41.PubMedCrossRef
10.
go back to reference Rorbach J, et al. Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res. 2008;36(9):3065–74.PubMedCrossRef Rorbach J, et al. Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res. 2008;36(9):3065–74.PubMedCrossRef
11.
go back to reference Lee JW, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443(7107):50–5.PubMedCrossRef Lee JW, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443(7107):50–5.PubMedCrossRef
12.
go back to reference Vogel CL, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37–42.PubMedCrossRef Vogel CL, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37–42.PubMedCrossRef
13.
go back to reference Nangle LA, Motta CM, Schimmel P. Global effects of mistranslation from an editing defect in mammalian cells. Chem Biol. 2006;13(10):1091–100.PubMedCrossRef Nangle LA, Motta CM, Schimmel P. Global effects of mistranslation from an editing defect in mammalian cells. Chem Biol. 2006;13(10):1091–100.PubMedCrossRef
14.
go back to reference Bacher JM, Schimmel P. An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response. Proc Natl Acad Sci USA. 2007;104(6):1907–12.PubMedCrossRef Bacher JM, Schimmel P. An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response. Proc Natl Acad Sci USA. 2007;104(6):1907–12.PubMedCrossRef
15.
go back to reference Ropcke G, Moen CJ, Hart AA, Demant P. Effects of the MHC on hormonal induction of mammary tumors and function of hypophyseal isografts in the mouse. Immunogenetics. 1990;31(5–6):347–55.PubMedCrossRef Ropcke G, Moen CJ, Hart AA, Demant P. Effects of the MHC on hormonal induction of mammary tumors and function of hypophyseal isografts in the mouse. Immunogenetics. 1990;31(5–6):347–55.PubMedCrossRef
16.
go back to reference Dux A, Demant P. MHC-controlled susceptibility to C3H-MTV-induced mouse mammary tumors is predominantly systemic rather than local. Int J Cancer. 1987;40(3):372–7.PubMedCrossRef Dux A, Demant P. MHC-controlled susceptibility to C3H-MTV-induced mouse mammary tumors is predominantly systemic rather than local. Int J Cancer. 1987;40(3):372–7.PubMedCrossRef
17.
go back to reference van Kooij M, de Groot K, van Vugt H, Aten J, Snoek M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics. 2001;53(8):656–61.PubMedCrossRef van Kooij M, de Groot K, van Vugt H, Aten J, Snoek M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics. 2001;53(8):656–61.PubMedCrossRef
18.
go back to reference Malkki M, Gooley T, Horowitz M, Petersdorf EW. MHC class I, II, and III microsatellite marker matching and survival in unrelated donor hematopoietic cell transplantation. Tissue Antigens. 2007;69(Suppl 1):46–9.PubMedCrossRef Malkki M, Gooley T, Horowitz M, Petersdorf EW. MHC class I, II, and III microsatellite marker matching and survival in unrelated donor hematopoietic cell transplantation. Tissue Antigens. 2007;69(Suppl 1):46–9.PubMedCrossRef
19.
go back to reference Harney SM, et al. Fine mapping of the MHC Class III region demonstrates association of AIF1 and rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1761–7.CrossRef Harney SM, et al. Fine mapping of the MHC Class III region demonstrates association of AIF1 and rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1761–7.CrossRef
20.
go back to reference Snoek M, Teuscher C, van Vugt H. Molecular analysis of the major MHC recombinational hot spot located within the G7c gene of the murine class III region that is involved in disease susceptibility. J Immunol. 1998;160(1):266–72.PubMed Snoek M, Teuscher C, van Vugt H. Molecular analysis of the major MHC recombinational hot spot located within the G7c gene of the murine class III region that is involved in disease susceptibility. J Immunol. 1998;160(1):266–72.PubMed
21.
go back to reference Fijneman RJ, Oomen LC, Snoek M, Demant PA. A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex. Immunogenetics. 1995;41(2-3):106–9.PubMedCrossRef Fijneman RJ, Oomen LC, Snoek M, Demant PA. A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex. Immunogenetics. 1995;41(2-3):106–9.PubMedCrossRef
22.
go back to reference Lanning D, Lafuse WP. The mouse p52 subunit of the transcription/DNA repair factor TFIIH is located in the class III region of the H2 complex: cloning and sequence polymorphism. Immunogenetics. 1999;49(6):498–504.PubMedCrossRef Lanning D, Lafuse WP. The mouse p52 subunit of the transcription/DNA repair factor TFIIH is located in the class III region of the H2 complex: cloning and sequence polymorphism. Immunogenetics. 1999;49(6):498–504.PubMedCrossRef
Metadata
Title
VARS2 V552V variant as prognostic marker in patients with early breast cancer
Authors
Yee Soo Chae
Soo Jung Lee
Joon Ho Moon
Byung Woog Kang
Jong Gwang Kim
Sang Kyun Sohn
Jin Hyang Jung
Ho Yong Park
Ji Young Park
Hye Jung Kim
Sang-Woo Lee
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9574-4

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.